Effects of Smoked Marijuana on Risk Taking and Decision Making Tasks
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00373399 |
Recruitment Status :
Completed
First Posted : September 8, 2006
Results First Posted : October 31, 2018
Last Update Posted : December 19, 2018
|
Sponsor:
New York State Psychiatric Institute
Collaborator:
National Institute on Drug Abuse (NIDA)
Information provided by (Responsible Party):
Margaret Haney, New York State Psychiatric Institute
- Study Details
- Tabular View
- Study Results
- Disclaimer
- How to Read a Study Record
Study Type | Interventional |
---|---|
Study Design | Allocation: Randomized; Intervention Model: Crossover Assignment; Masking: Double (Participant, Investigator); Primary Purpose: Basic Science |
Condition |
Marijuana Use Disorder |
Interventions |
Drug: Inactive Marijuana (0% THC) Drug: Low THC marijuana (1.8 %THC) Drug: High THC marijuana (3.9% THC) |
Enrollment | 36 |
Participant Flow
Recruitment Details | A total of 36 healthy research volunteers completed this three-session, within-subject outpatient study. Drug treatment was randomized. |
Pre-assignment Details |
Arm/Group Title | 0%, Then 1.98%, Then 3.56% THC | 0%, Then 3.56%, Then 1.98% THC | 1.98%, Then 0%, Then 3.56% THC | 1.98%, Then 3.56%, Then 0% THC | 3.56%, Then 0%, Then 1.98% THC | 3.56%, Then 1.98%, Then 0% THC |
---|---|---|---|---|---|---|
![]() |
A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. | A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. | A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. | A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. | A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. | A total of 36 volunteers completed this study. Drug treatment was randomized across 3 sessions so each period corresponds to each possible drug treatment. |
Period Title: Overall Study | ||||||
Started | 5 | 7 | 4 | 6 | 7 | 7 |
Completed | 5 | 7 | 4 | 6 | 7 | 7 |
Not Completed | 0 | 0 | 0 | 0 | 0 | 0 |
Baseline Characteristics
Arm/Group Title | Total Sample | |
---|---|---|
![]() |
A total of 36 participants completed the study | |
Overall Number of Baseline Participants | 36 | |
![]() |
A total of 36 participants completed the study. Baseline characteristics only available for the 36 completed participants.
|
|
Age, Categorical
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 36 participants | |
<=18 years |
0 0.0%
|
|
Between 18 and 65 years |
36 100.0%
|
|
>=65 years |
0 0.0%
|
|
Age, Continuous
Mean (Standard Deviation) Unit of measure: Years |
||
Number Analyzed | 36 participants | |
25.4 (4.0) | ||
Sex: Female, Male
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 36 participants | |
Female |
16 44.4%
|
|
Male |
20 55.6%
|
|
Race (NIH/OMB)
Measure Type: Count of Participants Unit of measure: Participants |
||
Number Analyzed | 36 participants | |
American Indian or Alaska Native |
0 0.0%
|
|
Asian |
0 0.0%
|
|
Native Hawaiian or Other Pacific Islander |
0 0.0%
|
|
Black or African American |
13 36.1%
|
|
White |
21 58.3%
|
|
More than one race |
2 5.6%
|
|
Unknown or Not Reported |
0 0.0%
|
|
Region of Enrollment
Measure Type: Count of Participants Unit of measure: Participants |
||
United States | Number Analyzed | 36 participants |
36 100.0%
|
Outcome Measures
Adverse Events
Limitations and Caveats
[Not Specified]
More Information
Results Point of Contact
Name/Title: | Margaret Haney |
Organization: | New York State Psychiatric Institute |
Phone: | 646-774-6153 |
EMail: | mh235@cumc.columbia.edu |
Responsible Party: | Margaret Haney, New York State Psychiatric Institute |
ClinicalTrials.gov Identifier: | NCT00373399 |
Other Study ID Numbers: |
IRB# 5204 DA-03746 ( Other Grant/Funding Number: National Institute on Drug Abuse ) |
First Submitted: | September 7, 2006 |
First Posted: | September 8, 2006 |
Results First Submitted: | August 7, 2017 |
Results First Posted: | October 31, 2018 |
Last Update Posted: | December 19, 2018 |